Sign in to confirm you’re not a bot
This helps protect our community. Learn more
These chapters are auto-generated

Introduction

0:00

MS 1819

0:23

Option 2 Trial

1:33

Capsule Type

2:16

Expectations for readout

3:07

Market size

3:41

Chronic pancreatitis

4:16

Key differentiating factor

8:19

When will the clinical trial start

9:05

How many trial sites

9:52

Emergency use authorization

10:31

Overall vs rectal formulations

10:58

When do you plan to start a trial

11:45

Are there any drugs on the market

12:56

How does Azeroth X plan to commercialize

14:21

Does Azeroth X have sufficient capital

15:31

Will you consider bringing additional candidates or indications for the pipeline

16:15

Closing remarks

16:38
H C Wainwright Global Life Sciences Conference Fireside Chat with James Sapirstein and Yi Chen 2021
6Likes
383Views
2021Mar 22

Follow along using the transcript.